

Outlook
With this favorable situation at the middle of the year, Eppendorf is confident that it will achieve growth well above the market average and further progress in the company's sustainable development for the entire 2018 financial year. Source: Eppendorf AG Press Release from August 3rd, 2018, https://corporate.eppendorf.com/en/news-media/press-releases/
More News

Pacira BioSciences Acquires GQ Bio
HTGF portfolio company GQ Bio, pioneering a high-capacity adenovirus gene therapy vector platform, was acquired by Pacira BioSciences, Inc. Pacira, the industry leader in its ...
Read more …
CrystalsFirst Scales Operations...
CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and ...
Read more …
Strategic cornerstone for medac: FDA approves treosulfan for alloHSCT
medac has received FDA approval for treosulfan as a new drug application with orphan drug designation prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...
Read more …